IBDEI1AS ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20750,1,4,0)
 ;;=4^G30.0
 ;;^UTILITY(U,$J,358.3,20750,2)
 ;;=^5003805
 ;;^UTILITY(U,$J,358.3,20751,0)
 ;;=G30.1^^95^1023^3
 ;;^UTILITY(U,$J,358.3,20751,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20751,1,3,0)
 ;;=3^Alzheimer's Disease w/ Late Onset
 ;;^UTILITY(U,$J,358.3,20751,1,4,0)
 ;;=4^G30.1
 ;;^UTILITY(U,$J,358.3,20751,2)
 ;;=^5003806
 ;;^UTILITY(U,$J,358.3,20752,0)
 ;;=B20.^^95^1023^21
 ;;^UTILITY(U,$J,358.3,20752,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20752,1,3,0)
 ;;=3^HIV Infection
 ;;^UTILITY(U,$J,358.3,20752,1,4,0)
 ;;=4^B20.
 ;;^UTILITY(U,$J,358.3,20752,2)
 ;;=^5000555
 ;;^UTILITY(U,$J,358.3,20753,0)
 ;;=G10.^^95^1023^22
 ;;^UTILITY(U,$J,358.3,20753,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20753,1,3,0)
 ;;=3^Huntington's Disease
 ;;^UTILITY(U,$J,358.3,20753,1,4,0)
 ;;=4^G10.
 ;;^UTILITY(U,$J,358.3,20753,2)
 ;;=^5003751
 ;;^UTILITY(U,$J,358.3,20754,0)
 ;;=G30.8^^95^1023^1
 ;;^UTILITY(U,$J,358.3,20754,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20754,1,3,0)
 ;;=3^Alzheimer's Disease NEC
 ;;^UTILITY(U,$J,358.3,20754,1,4,0)
 ;;=4^G30.8
 ;;^UTILITY(U,$J,358.3,20754,2)
 ;;=^5003807
 ;;^UTILITY(U,$J,358.3,20755,0)
 ;;=A81.89^^95^1023^5
 ;;^UTILITY(U,$J,358.3,20755,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20755,1,3,0)
 ;;=3^Atypical Virus Infections of CNS NEC
 ;;^UTILITY(U,$J,358.3,20755,1,4,0)
 ;;=4^A81.89
 ;;^UTILITY(U,$J,358.3,20755,2)
 ;;=^5000413
 ;;^UTILITY(U,$J,358.3,20756,0)
 ;;=G20.^^95^1023^69
 ;;^UTILITY(U,$J,358.3,20756,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20756,1,3,0)
 ;;=3^Parkinson's Disease
 ;;^UTILITY(U,$J,358.3,20756,1,4,0)
 ;;=4^G20.
 ;;^UTILITY(U,$J,358.3,20756,2)
 ;;=^5003770
 ;;^UTILITY(U,$J,358.3,20757,0)
 ;;=G23.1^^95^1023^73
 ;;^UTILITY(U,$J,358.3,20757,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20757,1,3,0)
 ;;=3^Progressive Supranuclear Ophthalmoplegia Palsy
 ;;^UTILITY(U,$J,358.3,20757,1,4,0)
 ;;=4^G23.1
 ;;^UTILITY(U,$J,358.3,20757,2)
 ;;=^5003780
 ;;^UTILITY(U,$J,358.3,20758,0)
 ;;=F03.91^^95^1023^17
 ;;^UTILITY(U,$J,358.3,20758,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20758,1,3,0)
 ;;=3^Dementia w/ Behavioral Disturbance,Unspec
 ;;^UTILITY(U,$J,358.3,20758,1,4,0)
 ;;=4^F03.91
 ;;^UTILITY(U,$J,358.3,20758,2)
 ;;=^5133350
 ;;^UTILITY(U,$J,358.3,20759,0)
 ;;=F03.90^^95^1023^19
 ;;^UTILITY(U,$J,358.3,20759,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20759,1,3,0)
 ;;=3^Dementia w/o Behavioral Disturbance,Unspec
 ;;^UTILITY(U,$J,358.3,20759,1,4,0)
 ;;=4^F03.90
 ;;^UTILITY(U,$J,358.3,20759,2)
 ;;=^5003050
 ;;^UTILITY(U,$J,358.3,20760,0)
 ;;=F02.81^^95^1023^40
 ;;^UTILITY(U,$J,358.3,20760,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20760,1,3,0)
 ;;=3^Major Neurocog D/O d/t Prob ALZHEIMER'S DISEASE w/ Behav Disturb
 ;;^UTILITY(U,$J,358.3,20760,1,4,0)
 ;;=4^F02.81
 ;;^UTILITY(U,$J,358.3,20760,2)
 ;;=^5003049
 ;;^UTILITY(U,$J,358.3,20761,0)
 ;;=F02.80^^95^1023^41
 ;;^UTILITY(U,$J,358.3,20761,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20761,1,3,0)
 ;;=3^Major Neurocog D/O d/t Prob ALZHEIMER'S DISEASE w/o Behav Disturb
 ;;^UTILITY(U,$J,358.3,20761,1,4,0)
 ;;=4^F02.80
 ;;^UTILITY(U,$J,358.3,20761,2)
 ;;=^5003048
 ;;^UTILITY(U,$J,358.3,20762,0)
 ;;=G31.84^^95^1023^56
 ;;^UTILITY(U,$J,358.3,20762,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20762,1,3,0)
 ;;=3^Mild Neurocog D/O d/t ALZHEIMER'S DISEASE
 ;;^UTILITY(U,$J,358.3,20762,1,4,0)
 ;;=4^G31.84
